NCT05287464Recruiting
International Multicentric Study ARON-1
Source: ClinicalTrials.gov · Last updated 26 Nov 2025
Brief summary (registry, in English)
The ARON-1 Study is designed as an International Multicentric Retrospective Study to collect global experiences with the use of immuno-combinations in patients with metastatic RCC. Two Supplementary Studies (ARON-1α and ARON-1β) have been designed. The ARON-1α Supplementary Study has been designed to investigate for the presence of genomic signatures from tumor samples of patients treated with first-line immuno-combinations for advanced RCC. The ARON-1β Supplementary Study has been designed to charaterize the immune cell populations and assess their relationship with the clinical outcome of mRCC patients treated with first-line immuno-combinations
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 1220 (estimated)
- First submitted
- 28 Feb 2022
- Start date
- 10 Mar 2022
- Primary completion date
- 1 Jun 2024
- Lead sponsor
- Hospital of Macerata
- Diseases
- Kidney cancer
- NCT number
- NCT05287464
What you commit to
- Study type: Observational
- Planned participants: 1220
- From 10 Mar 2022 to the primary completion date, 1 Jun 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients treated with immuno-combinations not included in the list reported in the Inclusion Criteria Section
Other illness
- Patients without histologically or radiologically confirmed metastatic disease
Other
- Patients without histologically confirmed diagnosis of RCC
Who the study is looking for
- Patients aged \>18y
- Cytological or Histologically confirmed diagnosis of clear cell or non-clear cell RCC
- Histologically or radiologically confirmed diagnosis of metastatic disease
- First-line treatment with nivolumab plus ipilimumab or nivolumab plus cabozantinib or pembrolizumab plus axitinib or pembrolizumab plus lenvatinib or avelumab plus axitinib or atezolizumab plus bevacizumab
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Ospedale di Macerata, UOC Oncologia Coordinator of this site? Confirm its status | Province of Macerata | Italy | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.